Allogene reports Q1 net loss $98.7M, cash $514M; clinical progress in ALLO-501A and ALLO-316

Allogene Therapeutics, Inc.

2023-Q1 EPS reported -$0.68 revenue$52,000

Net loss $98.7M ($0.68/share); R&D $80.2M, G&A $18.9M; cash $514M as of March 31, 2023.
Phase 2 ALPHA2 trial enrollment ongoing for ALLO-501A in R/R large B cell lymphoma; expects enrollment completion 1H 2024.
Initiated EXPAND trial to support licensure of ALLO-647; randomized ~70 patients to FCA90 vs FC alone before ALLO-501A.
Interim Phase 1 data on ALLO-316 in RCC: 3 of 10 CD70+ patients achieved partial response; disease control rate 100% in CD70+ subset.
Appointed Timothy Moore as Chief Technical Officer; fiscal 2023 guidance: cash burn ~$230M, GAAP OpEx ~$340M, runway into Q2 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 3, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.